Altfest L J & Co. Inc. Sells 4,944 Shares of Gilead Sciences, Inc. $GILD

Altfest L J & Co. Inc. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 72.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,915 shares of the biopharmaceutical company’s stock after selling 4,944 shares during the period. Altfest L J & Co. Inc.’s holdings in Gilead Sciences were worth $235,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Corundum Trust Company INC bought a new position in Gilead Sciences during the 3rd quarter valued at $26,000. Financial Consulate Inc. increased its position in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at $31,000. MTM Investment Management LLC increased its position in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Finally, Vision Financial Markets LLC increased its position in shares of Gilead Sciences by 123.1% during the 4th quarter. Vision Financial Markets LLC now owns 290 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 160 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the sale, the chief executive officer owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 299,280 shares of company stock worth $42,820,550. Insiders own 0.30% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Tubulis for up to $5 billion to expand its ADC oncology pipeline — a strategic bolt-on that supports Gilead’s shift into oncology and could drive longer‑term revenue growth. Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
• Positive Sentiment: Gilead exercised its option to license KT‑200 from Kymera, triggering a $45M milestone payment to Kymera and adding a first‑in‑class oral CDK2 degrader to its discovery-to-clinic pipeline — a validation of Gilead’s external innovation strategy. KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
• Positive Sentiment: Research partners and collaborations: expanded RWE and oncology R&D tie-ups (Tempus, Cartography) reinforce Gilead’s push to accelerate translational work and de‑risk discovery-stage assets. Tempus Announces Strategic Collaboration with Gilead
• Positive Sentiment: Sell-side lifts and bullish notes: Morgan Stanley raised its price target to $175 with an overweight rating (largest upside among today’s notes), and Truist also nudged up its target — these analyst actions can support buying interest. Price target raise at Morgan Stanley (Benzinga)
• Neutral Sentiment: Short‑interest data for April is effectively meaningless/zero in the report (shows 0 shares / NaN change), so it doesn’t provide directional insight into current positioning.
• Negative Sentiment: Cantor Fitzgerald cut its price target sharply to $115 (while oddly maintaining an overweight rating), introducing downside headline risk and signaling divergent analyst views on valuation. Cantor Fitzgerald Adjusts Price Target on Gilead Sciences
• Negative Sentiment: The AIDS Healthcare Foundation publicly criticized Gilead over its role in a Florida drugs situation — reputational and regulatory scrutiny can pressure sentiment and potentially elevate legal/regulatory risk. AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Gilead Sciences Trading Up 0.0%

Shares of GILD opened at $139.03 on Monday. The business has a 50-day moving average of $145.13 and a 200 day moving average of $130.59. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29. The firm has a market cap of $172.56 billion, a P/E ratio of 20.54, a price-to-earnings-growth ratio of 1.85 and a beta of 0.39. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter last year, the firm posted $1.90 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a $0.82 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s payout ratio is 48.45%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GILD. Oppenheimer raised their target price on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Wolfe Research raised their target price on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Morgan Stanley raised their target price on Gilead Sciences from $171.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday, March 6th. Finally, UBS Group raised their target price on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $156.42.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.